Since the current PCSK9 inhibitors have been used in clinic, and the incidence of subsequent related tumors in these patients can be compared in a prospective study to help prove the potential of PCSK9 in tumor immunotherapy. This evidence concerns the gene PCSK9 and neoplasm.